e-Therapeutics Plc (ETX.L) posted loss attributable to equity holders of the company of 3.24 million pounds for the year ended January 31, 2012 compared to the loss of 2.31 million pounds last year. Meanwhile, loss per share narrowed to 2.47 pence from 3.51 pence in the prior year.
Pre-tax loss widened to 3.86 million pounds from 2.66 million pounds in the previous year.
The company did not record any revenues for the year.
e-Therapeutics' CFO, Dr Daniel Elger, said, "Our 2012 results reflect increasing investment in drug discovery and drug development made possible by shareholders' support of a significant capital raise during the year. We are confident that continuing this investment will yield promising new drugs and advance our pipeline towards value-realising partnering deals."
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.